CSE($CDN) XRX (Delayed) OTC($USD) XRTXF

Press Releases

XORTX Announces Submission of Orphan Drug Designation Application

Posted on: 11th September 2018

Phase II Clinical Study in ADPKD Planned CALGARY, Alberta, Sept. 10, 2018 (GLOBE NEWSWIRE) —  XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE:XRX; OTCQB:XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce that the Company along with its collaborative partner, Cato Clinical Research, has submitted documents..More

QBIE™ Spotlight: XORTX Therapeutics Inc. (OTCQB: XRTXF)

Posted on: 22nd August 2018

QBie™ Spotlight joins Dr. Allen Davidoff, CEO, of XORTX Therapeutics Inc. (OTCQB: XRTXF), to discuss one of the OTCQB’s newest additions. XORTX joined the OTCQB on June 7, 2018. See the full article here (will open in a new tab).

XORTX Submits FDA pre-IND Meeting Documents

Posted on: 13th August 2018

● Advancing to a Phase II Clinical Study in Polycystic Kidney Disease ● CALGARY, Alberta, Aug. 13, 2018 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE:XRX; OTCQB:XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce that the Company with its collaborative partner, Cato..More

XORTX Reports on Annual Special Meeting and Provides Corporate Update

Posted on: 28th June 2018

CALGARY, Alberta, June 28, 2018 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE:XRX) (OTCQB:XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to provide the results of the Company’s annual and special meeting of shareholders and to provide a corporate update and summary of activities since..More

XORTX Announces Filing of FDA pre-IND Meeting Request Letter

Posted on: 8th June 2018

CALGARY, Alberta, June 08, 2018 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE:XRX) (OTCQB:XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce the Company along with Cato Clinical Research has filed its pre-IND meeting request letter with the FDA. The request for a..More

XORTX to Commence Trading on the OTCQB Venture Market

Posted on: 6th June 2018

CALGARY, Alberta, June 06, 2018 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE:XRX) (OTCQB:XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce that the Company’s shares have been approved to commence trading on the OTCQB Venture Market under the symbol XRTXF effective June..More

XORTX Appoints Chairman

Posted on: 8th May 2018

CALGARY, AB – May 8, 2018 – XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE:XRX), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce the appointment of Bruce Rowlands, a director of XORTX as Chairman of the Board of Directors. Bruce Rowlands has extensive experience in the..More

XORTX Announces PKD Foundation Collaboration

Posted on: 19th April 2018

CALGARY, AB – April 19, 2018 – XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE:XRX) is pleased to announce that the PKD Foundation has recognized XORTX as a leader in advancing the development of treatments for progressive kidney disease, including polycystic kidney disease (“PKD”) and rare diseases such as autosomal dominant polycystic kidney disease (“ADPKD”)...More

Latest Press Releases

Archives